Clinical trials: Neurogenic Orthostatic Hypotension
Orthostatic; Hypotension, Neurogenic
Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study
Compare the effect of treatment of midodrine and pyridostigmine in neurogenic orthostatic hypotension and investigate the quality of life of treatment of neurogenic orthostatic hypotension.
- Trial name
- NCT02308124
- Testing
- Midodrine, Pyridostigmine Bromide, Midodrine + pyridostigmine
- Where
- South Korea
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Neurogenic Orthostatic Hypotension
Controlled CO2 Inhalation in NOH
This study focuses on neurogenic orthostatic hypotension (nOH), which is a disorder characterized by an abnormal drop in blood pressure (BP) within 3-minutes of standing.
- Trial name
- CO2-nOH (NCT06751888)
- Testing
- Controlled CO2 delivery
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- University of Calgary
Neurogenic Orthostatic Hypotension
Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension
To evaluate the efficacy of a 4-week fludrocortisone (FLU) treatment on systolic blood pressure depression after 5 minutes of active orthostatism in patients with neurogenic orthostatic hypotension (HON) symptomatic, despite…
- Trial name
- NCT04128137
- Testing
- Fludrocortisone
- Where
- France
- Volunteers
- 90 people
- Sponsor
- H.A.C. PHARMA
Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease
A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy
Evaluate the clinical efficacy and safety of droxidopa versus placebo over a 17 week (maximum) treatment period in patients with symptomatic NOH.
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease, Multiple Systems Atrophy, Pure Autonomic Failure
- Trial name
- NCT01927055
- Testing
- Droxidopa
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- Chelsea Therapeutics
Neurogenic Orthostatic Hypotension
Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)
Drug therapy for patients suffering from autonomic failure and neurogenic orthostatic hypotension are scarce and not effective. If left untreated, these patients have the highest risk of syncope, falls and fall-related injuries.
- Trial name
- NETAF (NCT02784535)
- Testing
- Atomoxetine
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Vanderbilt University Medical Center
Hypotension, Orthostatic, Hypotension
Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury
The goal of this study is to determine the efficacy of the drug Droxidopa (Northera) in increasing blood pressure in subject with hypotension, low blood pressure, which is classified as blood pressure less than 110/70 in males…
- Conditions
- Hypotension, Orthostatic, Hypotension, Spinal Cord Injuries
- Trial name
- NCT03602014
- Testing
- Northera
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Hypotension, Orthostatic
Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension
The purpose of this clinical study is to evaluate the clinical effect of midodrine hydrochloride (ProAmatine®) compared to placebo in patients with orthostatic hypotension by measuring the time to onset of near syncopal symptoms…
- Trial name
- NCT00555880
- Testing
- Midodrine hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire
Hypotension, Orthostatic
A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension
We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright…
- Trial name
- NCT00046163
- Testing
- midodrine hydrochloride (ProAmatine®)
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Shire
Parkinson Disease (PD), REM Sleep Behavior Disorder (iRBD)
Artificial Intelligence-based Parkinson's Disease Risk Assessment (AI-PRA) Study
The study aims to provide initial proof-of-concept validation data of an artificial intelligence-based model to estimate individual Parkinson's disease risk using demographic, clinical, genetic information and digital biomarker…
- Conditions
- Parkinson Disease (PD), REM Sleep Behavior Disorder (iRBD), Neurogenic Orthostatic Hypotension, Hyposmia
- Trial name
- AI-PRA (NCT07706829)
- Testing
- Smartwatch and phone app
- Where
- 3 sites in France, Spain and 1 more
- Volunteers
- 60 people
- Sponsor
- Queen Mary University of London
Multiple System Atrophy, Autonomic Failure
Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
Patients referred to neurosurgery routinely and safely undergo deep brain stimulation (DBS) for treatment of symptoms related to neurodegenerative conditions, most commonly Parkinson's disease.
- Conditions
- Multiple System Atrophy, Autonomic Failure, Postural Hypotension, Bladder, Neurogenic
- Trial name
- STAG-MSA (NCT03593512)
- Testing
- Deep brain stimulation
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- University of Oxford
Spinal Cord Injury, Autonomic Dysfunction
Non-invasive Spinal Cord Stimulation for Recovery of Autonomic Function After Spinal Cord Injury
This study is a pilot clinical trial to explore the efficacy of transcutaneous spinal cord stimulation (TCSCS) (proof-of-concept) in mitigating crucial autonomic dysfunctions that impact the health-related quality of life of…
- Conditions
- Spinal Cord Injury, Autonomic Dysfunction, Sexual Dysfunction, Neurogenic Bladder Dysfunction
- Trial name
- NCT05369520
- Testing
- TESCoN or SCONE device - Thoracic stimulation, TESCoN or SCONE device - Lumbosacral stimulation
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Symptomatic Neurogenic Orthostatic Hypotension, MSA
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Trial name
- REDWOOD (NCT03829657)
- Testing
- ampreloxetine
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 203 people
- Sponsor
- Theravance Biopharma
Neurogenic Orthostatic Hypotension
Sinusoidal Galvanic Vestibular Stimulation for Neurogenic Orthostatic Hypotension / Syncope
Neurogenic orthostatic hypotension occurs in a significant number of people and has no effective treatment. Neurogenic orthostatic hypotension is associated with intermittent episodes of fainting which can be debilitating for the…
- Trial name
- NCT04976101
- Testing
- Sinosuidal Galvanic Vestibular Stimulation
- Where
- United States
- Sponsor
- Hackensack Meridian Health
Orthostatic; Hypotension, Neurogenic, Autonomic Failure
Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
The objective of this study is to find a more objective and accurate way to assess the efficacy of the treatment for neurogenic orthostatic hypotension.
- Conditions
- Orthostatic; Hypotension, Neurogenic, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy
- Trial name
- NCT04782830
- Testing
- Accelerometer, Midodrine or atomoxetine pill
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Vanderbilt University Medical Center
Neurogenic Orthostatic Hypotension
A Study in Subjects With Neurogenic Orthostatic Hypotension
This is a study to evaluate the effects of CST-3056 on orthostatic symptoms and signs in subjects with neurogenic orthostatic hypotension (nOH).
- Trial name
- NCT07089043
- Testing
- CST-3056
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- CuraSen Therapeutics, Inc.
Symptomatic Neurogenic Orthostatic Hypotension
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
- Trial name
- OAK (NCT04095793)
- Testing
- ampreloxetine
- Where
- 55 sites in United States, Australia and 16 more
- Volunteers
- 110 people
- Sponsor
- Theravance Biopharma
Patients With Synucleinopathies, Neurogenic Orthostatic Hypotension
Natural History Study of Synucleinopathies
Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumulation of the protein α-synuclein in the nervous system. Onset is usually in late adulthood at age 50 or older.
- Conditions
- Patients With Synucleinopathies, Neurogenic Orthostatic Hypotension, Pure Autonomic Failure, REM Sleep Behavior Disorder
- Trial name
- NCT01799915
- Where
- 8 sites in United States, Argentina and 2 more
- Volunteers
- 800 people
- Sponsor
- NYU Langone Health
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic…
- Conditions
- Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease
- Trial name
- NCT02705755
- Testing
- TD-9855
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Theravance Biopharma
Chronic Fatigue Syndrome, Orthostatic Hypotension
Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
A subset of patients suffering from chronic fatigue syndrome exhibit symptoms of neurally mediated hypotension. While the underlying pathophysiology of chronic fatigue syndrome is not precisely understood, a dysfunction of the…
- Conditions
- Chronic Fatigue Syndrome, Orthostatic Hypotension, Neurally Mediated Hypotension, Neurogenic Orthostatic Hypotension
- Trial name
- CFS201 (NCT00977171)
- Testing
- Droxidopa
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Chelsea Therapeutics
Hypotension, Orthostatic
A Study for Patients With Neurogenic Orthostatic Hypotension
We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright…
- Trial name
- NCT00046475
- Testing
- Midodrine Hydrochloride
- Where
- 15 sites in United States
- Volunteers
- 140 people
- Sponsor
- Shire